Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck’s Keytruda yields mixed results in phase 3 KEYNOTE-062 trial
In the monotherapy arm of the study, KEYTRUDA met a primary endpoint by demonstrating noninferiority to chemotherapy, the current standard of care, for overall survival (OS) in the
In the monotherapy arm of the study, KEYTRUDA met a primary endpoint by demonstrating noninferiority to chemotherapy, the current standard of care, for overall survival (OS) in the
Smart Pharma will operate Smart-ACT, a computational repurposed drug discovery, modeling and validation platform, which uses latest technology for systematic screening of existing approved drug molecules against certain
The Israeli pharma came to the decision after a pre-specified futility analysis showed that fremanezumab was unlikely to meet the primary endpoint of a phase 3 trial in
The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta (axicabtagene ciloleucel), Kite’s first commercially available
Taltz met the primary and all key secondary endpoints in the late-stage trial, called COAST-X. The 52-week trial evaluated the safety and efficacy of the psoriatic arthritis drug
Under the terms of the agreement, Lilly will receive a deposit of $75 million, followed by a payment of $300 million upon successful closing of the transaction. As
Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Overactive bladder (OAB) is
Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF technology process. Under the strategic partnership with AqVida, Phyton Biotech will
iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology,
The company said that it used a priority review voucher to fast track the review of the regulator on brolucizumab in order to make it available to patients